Natural Product (NP) Details
General Information of the NP (ID: NP9072) | |||||
---|---|---|---|---|---|
Name |
Doxercalciferol
|
||||
Synonyms |
Doxercalciferol; 54573-75-0; Hectorol; 1alpha-Hydroxyergocalciferol; 1-Hydroxyergocalciferol; 1alpha-hydroxyvitamin D2; 1-alpha-Hydroxyvitamin D2; TSA 840; 1-Hydroxyvitamin D2; UNII-3DIZ9LF5Y9; 1alpha-OH-D2; 3DIZ9LF5Y9; 1-alpha-hydroxyergocalciferol; CHEBI:4712; (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; MFCD00871065; 1alpha-hydroxyvitamin D2 / 1alpha-hydroxyergocalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol; Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; 1alpha-OHD2; BRN 4716774; Doxercalciferol [USAN:INN]; Vitamin D2, 1alpha-Hydroxy-; Doxercalciferolum; NCGC00182058-03; 1alphaOHD2; PubChem18823; 1alpha-hydroxy vitamin D2; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-alpha-hydroxy-vitamin D2; DSSTox_CID_14214; DSSTox_RID_79125; Doxercalciferol (USAN/INN); DSSTox_GSID_34214; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; SCHEMBL322422; GTPL2790; CHEMBL1200810; DTXSID1034214; TSA-840; ACT06836; EX-A4428; ZINC4641374; Tox21_112978; HSCI1_000341; LMST03010028; AKOS005146517; CS-0395; DB06410; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-; BS-17040; GZ427397; HY-32348; CAS-54573-75-0; V1826; C08211; D01009; W-5181; 42163-EP2298768A1; 42163-EP2311808A1; 42163-EP2311829A1; 573D750; Q5303688; Doxercalciferol, >=98% (HPLC), solubility: >10 mg/mL in DMSO; Doxercalciferol, United States Pharmacopeia (USP) Reference Standard; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1alpha,3beta,5Z,7E,22E)-; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7?-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7alpha-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Chronic kidney disease [ICD-11: GB61] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C28H44O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
||||
InChI |
1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
|
||||
InChIKey |
HKXBNHCUPKIYDM-CGMHZMFXSA-N
|
||||
CAS Number |
CAS 54573-75-0
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
KML001 | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
A combination of KML001 with doxercalciferol showed a synergistic effect on ALL cell lines. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Vitamin D3 receptor (VDR) | Molecule Info | [3] | |
KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | Click to Show/Hide | ||
2 | Mineral absorption | |||
3 | Tuberculosis | |||
NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Vitamin D metabolism and pathway | Click to Show/Hide | ||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Direct p53 effectors | |||
3 | RXR and RAR heterodimerization with other nuclear receptor | |||
4 | Retinoic acid receptors-mediated signaling | |||
5 | Validated transcriptional targets of deltaNp63 isoforms | |||
6 | Validated transcriptional targets of TAp63 isoforms | |||
Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
WikiPathways | Ovarian Infertility Genes | Click to Show/Hide | ||
2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
3 | Nuclear Receptors Meta-Pathway | |||
4 | Vitamin D Receptor Pathway | |||
5 | Drug Induction of Bile Acid Pathway | |||
6 | Nuclear Receptors | |||
7 | Vitamin D Metabolism |
